Abstract
Implementation of the high-throughput microarray gene expression profiling technology towards "toxicogenomics" has advanced identification process for safer drugs in the century of omics technology. Applying such technology, in fact, to identify mechanisms for cellular toxicity can provide a means to clarify safety liabilities early in the drug discovery and developments process. The underlying principle in gene therapy is primarily targeting a specific gene (e.g., for silencing). Hence, massive efforts have been devoted to validate the gene-based therapeutics, regardless of toxicogenomics potential of delivery systems. Of the gene delivery systems, viral and non-viral vectors, as two main paradigms, have so far been widely used for delivering of the genome-based therapeutics such as oligonucleotide, small interfering RNA and DNA. However, the use of viral vectors was narrowed due to the safety concerns. Non-viral vectors were utilized as safer alternatives for gene delivery in vitro and ex-vivo; though their success for in vivo gene therapy has been limited due to low efficiency and safety issues. Fundamental principle for gene therapy is to deliver gene-based therapeutics into target cells for specific gene targeting ideally with minimal cellular toxicity. Until now, few works have been conducted about geno-compatibility of delivery systems itself, including cationic lipid-based nanosystems. Inadvertent toxicogenomic impact of gene delivery systems (e.g., cationic lipids) may intrinsically affect the outcome of gene therapy, where often only a single desired genetic change is sought. Further, there exists a possibility that gene changes induced by the lipid delivery system itself could exacerbate, attenuate or even mask the desired effects of the gene-based therapeutics. This review will focus on toxicogenomics impact of the cationic lipid-based formulations for gene therapy.
Keywords: cationic lipids, microarray, gene delivery, gene expression profiling, gene therapy, genotoxicity, genocompatibility, toxicogenomics, lipid-based nanosystems
Current Drug Delivery
Title: Toxicogenomics of Cationic Lipid-based Vectors for Gene Therapy: Impact of Microarray Technology
Volume: 2 Issue: 4
Author(s): Yadollah Omidi, Jaleh Barar and Saghir Akhtar
Affiliation:
Keywords: cationic lipids, microarray, gene delivery, gene expression profiling, gene therapy, genotoxicity, genocompatibility, toxicogenomics, lipid-based nanosystems
Abstract: Implementation of the high-throughput microarray gene expression profiling technology towards "toxicogenomics" has advanced identification process for safer drugs in the century of omics technology. Applying such technology, in fact, to identify mechanisms for cellular toxicity can provide a means to clarify safety liabilities early in the drug discovery and developments process. The underlying principle in gene therapy is primarily targeting a specific gene (e.g., for silencing). Hence, massive efforts have been devoted to validate the gene-based therapeutics, regardless of toxicogenomics potential of delivery systems. Of the gene delivery systems, viral and non-viral vectors, as two main paradigms, have so far been widely used for delivering of the genome-based therapeutics such as oligonucleotide, small interfering RNA and DNA. However, the use of viral vectors was narrowed due to the safety concerns. Non-viral vectors were utilized as safer alternatives for gene delivery in vitro and ex-vivo; though their success for in vivo gene therapy has been limited due to low efficiency and safety issues. Fundamental principle for gene therapy is to deliver gene-based therapeutics into target cells for specific gene targeting ideally with minimal cellular toxicity. Until now, few works have been conducted about geno-compatibility of delivery systems itself, including cationic lipid-based nanosystems. Inadvertent toxicogenomic impact of gene delivery systems (e.g., cationic lipids) may intrinsically affect the outcome of gene therapy, where often only a single desired genetic change is sought. Further, there exists a possibility that gene changes induced by the lipid delivery system itself could exacerbate, attenuate or even mask the desired effects of the gene-based therapeutics. This review will focus on toxicogenomics impact of the cationic lipid-based formulations for gene therapy.
Export Options
About this article
Cite this article as:
Omidi Yadollah, Barar Jaleh and Akhtar Saghir, Toxicogenomics of Cationic Lipid-based Vectors for Gene Therapy: Impact of Microarray Technology, Current Drug Delivery 2005; 2 (4) . https://dx.doi.org/10.2174/156720105774370249
DOI https://dx.doi.org/10.2174/156720105774370249 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly
Current Pharmaceutical Analysis Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics A Summary of Computational Resources for Protein Phosphorylation
Current Protein & Peptide Science Formulation and Optimization of 5-Fluorouracil Loaded Chitosan Nanoparticles Employing Central Composite Design
Drug Delivery Letters Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Development of a Reproducible, Sensitive and Rapid Reversed Phase Chromatographic Method for the Estimation of Isotretinoin Incorporated in Bulk Drugs, Pharmaceutical Dosage Forms and Biological Matrix
Current Pharmaceutical Analysis Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Characterization of Some New Thiazole based Thiazolidinone Derivatives as Potent Antimicrobial and Antimycobacterial Agents
Anti-Infective Agents A Role for Milk Proteins and their Peptides in Cancer Prevention
Current Pharmaceutical Design Mini Heme-Proteins: Designability of Structure and Diversity of Functions
Current Protein & Peptide Science Research/Review: Structure and Linkage Disequilibrium Analysis of Adamantane Resistant Mutations in Influenza Virus M2 Proton Channel
Current Drug Metabolism Structure-Bioactivity Relationship Study of Xanthene Derivatives: A Brief Review
Current Organic Synthesis Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry Evaluating Five <i>Escherichia coli</i> Derivative Strains as a Platform for Arginine Deiminase Overproduction
Recent Patents on Biotechnology A Sensitive Determination of Ammonia and Nitrite in Exhaled Breath Condensate of Healthy Humans by Using Berthelot Reaction
Current Pharmaceutical Analysis Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry